Prevalence and Risk Factors for Secondary Hypertension in Young Adults.

body mass index diabetes mellitus hyperaldosteronism hypertension hypokalemia

Journal

Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255

Informations de publication

Date de publication:
19 Sep 2024
Historique:
medline: 19 9 2024
pubmed: 19 9 2024
entrez: 19 9 2024
Statut: aheadofprint

Résumé

The prevalence of secondary causes of hypertension in young adults is unknown, and therefore, there is no consensus about the indication of screening of secondary hypertension (2HTN) in this population. The objective was to report the prevalence and the causes of 2HTN in young subjects. 2090 patients with confirmed hypertension aged 18 to 40 years with full workup for 2HTN screening were included in this cross-sectional study. We assessed the prevalence of 2HTN and analyzed the factors associated. 619/2090 patients (29.6%) had a 2HTN. The most frequent diagnoses of 2HTN in descending order were primary aldosteronism (n=339; 54.8%), renovascular hypertension (n=114; 18.4%), primary kidney disease (n=80; 12.9%), pheochromocytoma/functional paraganglioma (n=37; 5.9%), hypertension caused by drugs or substances (n=32; 6.0%), and other diagnoses (n=17; 2.7%). Patients with blood pressure <160/100 mm Hg did not have a lower prevalence of 2HTN regardless of the number of treatments. The prevalence of 2HTN was higher in the decade between 30 and 40 years of age than between 18 and 30 years of age ( The prevalence of 2HTN is high among young patients with hypertension (29.6% in our cohort), regardless of age and blood pressure level. All patients with hypertension under 40 years of age should be screened for secondary causes.

Sections du résumé

BACKGROUND UNASSIGNED
The prevalence of secondary causes of hypertension in young adults is unknown, and therefore, there is no consensus about the indication of screening of secondary hypertension (2HTN) in this population. The objective was to report the prevalence and the causes of 2HTN in young subjects.
METHODS UNASSIGNED
2090 patients with confirmed hypertension aged 18 to 40 years with full workup for 2HTN screening were included in this cross-sectional study. We assessed the prevalence of 2HTN and analyzed the factors associated.
RESULTS UNASSIGNED
619/2090 patients (29.6%) had a 2HTN. The most frequent diagnoses of 2HTN in descending order were primary aldosteronism (n=339; 54.8%), renovascular hypertension (n=114; 18.4%), primary kidney disease (n=80; 12.9%), pheochromocytoma/functional paraganglioma (n=37; 5.9%), hypertension caused by drugs or substances (n=32; 6.0%), and other diagnoses (n=17; 2.7%). Patients with blood pressure <160/100 mm Hg did not have a lower prevalence of 2HTN regardless of the number of treatments. The prevalence of 2HTN was higher in the decade between 30 and 40 years of age than between 18 and 30 years of age (
CONCLUSIONS UNASSIGNED
The prevalence of 2HTN is high among young patients with hypertension (29.6% in our cohort), regardless of age and blood pressure level. All patients with hypertension under 40 years of age should be screened for secondary causes.

Identifiants

pubmed: 39297209
doi: 10.1161/HYPERTENSIONAHA.124.22753
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jean-Baptiste de Freminville (JB)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).
INSERM, UMRS 1138, CRC, Université Sorbonne-Paris Cité, France (J.-B.d.F., B.R.).

Margherita Gardini (M)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).

Antoine Cremer (A)

Hypertension Excellence Center, University Hospital of Bordeaux, Hopital Saint André, France (A.C., P.G., J.D., T.D.).

Scarlett Camelli (S)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).
Hopital Privé Seine Saint Denis, Drancy, France (S.C.).

Stephanie Baron (S)

Physiology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (S.B.).
Inserm, Paris, France (S.B.).

Guillaume Bobrie (G)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).
Service de Néphrologie Hémodialyse, Hôpital Privé du Vert Galant, Ramsay Générale de Santé-Tremblay-en-France (G.B.).

Philippe Gosse (P)

Hypertension Excellence Center, University Hospital of Bordeaux, Hopital Saint André, France (A.C., P.G., J.D., T.D.).

Romain Boulestreau (R)

Service des Maladies Coronaires et Vasculaires, CHU de Bordeaux, France (R.B.).

Nicole Gebara (N)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).

Julien Doublet (J)

Hypertension Excellence Center, University Hospital of Bordeaux, Hopital Saint André, France (A.C., P.G., J.D., T.D.).

Thomas Dussartre (T)

Hypertension Excellence Center, University Hospital of Bordeaux, Hopital Saint André, France (A.C., P.G., J.D., T.D.).

Christine Grataloup (C)

Radiology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (C.G., G.S.).

Aurélien Lorthioir (A)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).

Christine Massien (C)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).

Anne-Marie Madjalian (AM)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).

Julien Riancho (J)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).

Gilles Soulat (G)

Radiology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (C.G., G.S.).

Nicolas Postel-Vinay (N)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).

Michel Azizi (M)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).
Inserm CIC 1418, Paris, France (M.A.).

Bastien Rance (B)

Medical Informatics, Biostatistics and Public Health Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (B.R.).
INSERM, UMRS 1138, CRC, Université Sorbonne-Paris Cité, France (J.-B.d.F., B.R.).
INRIA, Le Chesnay-Rocquencourt, France (B.R.).

Laurence Amar (L)

Hypertension Unit, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France. (J.-B.d.F., M.G., S.C., G.B., N.G., A.L., C.M., A.-M.M., J.R., N.P.-V., M.A., L.A.).
Adrenal Referral Center, AP-HP, Université Paris Cité, France (L.A.).
Inserm Paris Cardiovascular Research Center, France (L.A.).

Classifications MeSH